CN113907340A - Lactose-free infant formula and preparation method thereof - Google Patents
Lactose-free infant formula and preparation method thereof Download PDFInfo
- Publication number
- CN113907340A CN113907340A CN202111231618.5A CN202111231618A CN113907340A CN 113907340 A CN113907340 A CN 113907340A CN 202111231618 A CN202111231618 A CN 202111231618A CN 113907340 A CN113907340 A CN 113907340A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactose
- powder
- free
- infant formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 108
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 60
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 53
- 235000013305 food Nutrition 0.000 claims abstract description 33
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 30
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 30
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 24
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 23
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 23
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 23
- 235000008939 whole milk Nutrition 0.000 claims abstract description 22
- 235000020357 syrup Nutrition 0.000 claims abstract description 21
- 239000006188 syrup Substances 0.000 claims abstract description 21
- 239000002773 nucleotide Substances 0.000 claims abstract description 20
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 20
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 17
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 17
- 239000011707 mineral Substances 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 239000001656 lutein Substances 0.000 claims abstract description 15
- 235000012680 lutein Nutrition 0.000 claims abstract description 15
- 229960005375 lutein Drugs 0.000 claims abstract description 15
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 15
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 15
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 15
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 15
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 13
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 12
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 12
- 235000021119 whey protein Nutrition 0.000 claims abstract description 12
- 240000008042 Zea mays Species 0.000 claims abstract description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 10
- 235000005822 corn Nutrition 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 10
- -1 compound vitamin Chemical class 0.000 claims abstract description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 18
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 18
- 239000008158 vegetable oil Substances 0.000 claims description 18
- 235000010755 mineral Nutrition 0.000 claims description 16
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000005018 casein Substances 0.000 claims description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 11
- 235000021240 caseins Nutrition 0.000 claims description 11
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 10
- 235000020778 linoleic acid Nutrition 0.000 claims description 10
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 125000005456 glyceride group Chemical group 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 9
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 9
- 239000001508 potassium citrate Substances 0.000 claims description 9
- 229960002635 potassium citrate Drugs 0.000 claims description 9
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 9
- 235000011082 potassium citrates Nutrition 0.000 claims description 9
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- 239000002285 corn oil Substances 0.000 claims description 7
- 235000005687 corn oil Nutrition 0.000 claims description 7
- 238000007580 dry-mixing Methods 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims description 6
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- 239000011665 D-biotin Substances 0.000 claims description 6
- 235000000638 D-biotin Nutrition 0.000 claims description 6
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 6
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 6
- 108010059881 Lactase Proteins 0.000 claims description 6
- 241000907999 Mortierella alpina Species 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229960004874 choline bitartrate Drugs 0.000 claims description 6
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 6
- 235000019864 coconut oil Nutrition 0.000 claims description 6
- 239000003240 coconut oil Substances 0.000 claims description 6
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 6
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 6
- 239000011666 cyanocobalamin Substances 0.000 claims description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 239000011706 ferric diphosphate Substances 0.000 claims description 6
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 6
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 6
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 239000000413 hydrolysate Substances 0.000 claims description 6
- 229940116108 lactase Drugs 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 229940099596 manganese sulfate Drugs 0.000 claims description 6
- 239000011702 manganese sulphate Substances 0.000 claims description 6
- 235000007079 manganese sulphate Nutrition 0.000 claims description 6
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 6
- 229960000342 retinol acetate Drugs 0.000 claims description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 6
- 235000019173 retinyl acetate Nutrition 0.000 claims description 6
- 239000011770 retinyl acetate Substances 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000019192 riboflavin Nutrition 0.000 claims description 6
- 239000002151 riboflavin Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000011781 sodium selenite Substances 0.000 claims description 6
- 235000015921 sodium selenite Nutrition 0.000 claims description 6
- 229960001471 sodium selenite Drugs 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 6
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 6
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 6
- 235000005282 vitamin D3 Nutrition 0.000 claims description 6
- 239000011647 vitamin D3 Substances 0.000 claims description 6
- 235000012711 vitamin K3 Nutrition 0.000 claims description 6
- 239000011652 vitamin K3 Substances 0.000 claims description 6
- 229940021056 vitamin d3 Drugs 0.000 claims description 6
- 229940041603 vitamin k 3 Drugs 0.000 claims description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 6
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 6
- 229960001763 zinc sulfate Drugs 0.000 claims description 6
- 241000195493 Cryptophyta Species 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- 235000021323 fish oil Nutrition 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 3
- 235000019519 canola oil Nutrition 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 229950006790 adenosine phosphate Drugs 0.000 claims description 2
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 claims description 2
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 claims description 2
- INTPYBRGLGSMRA-WFIJOQBCSA-L disodium cytidine 5'-monophosphate Chemical compound [Na+].[Na+].O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])([O-])=O)O1 INTPYBRGLGSMRA-WFIJOQBCSA-L 0.000 claims description 2
- 235000013896 disodium guanylate Nutrition 0.000 claims description 2
- 235000013890 disodium inosinate Nutrition 0.000 claims description 2
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 claims description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 238000009928 pasteurization Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- 239000011755 sodium-L-ascorbate Substances 0.000 claims description 2
- 235000019187 sodium-L-ascorbate Nutrition 0.000 claims description 2
- 235000020247 cow milk Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 201000010538 Lactose Intolerance Diseases 0.000 abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 235000019484 Rapeseed oil Nutrition 0.000 description 5
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 235000020214 lactose-free milk formula Nutrition 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108700016492 Congenital Lactase Deficiency Proteins 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000005161 congenital lactase deficiency Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009448 modified atmosphere packaging Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a lactose-free infant formula food which comprises the following raw materials in parts by weight: 40-50 parts of vegetable fat powder; 25-40 parts of solid corn syrup and/or maltodextrin; 10-20 parts of lactose-free whole milk powder; 2-10 parts of separated whey protein powder rich in alpha-lactalbumin; 0.4-0.9 part of docosahexaenoic acid powder; 0.5-0.9 part of arachidonic acid powder; 2.0-3.0 parts of compound mineral; 0.3-0.7 part of compound vitamin; 0-0.05 part of nucleotide; 0-0.03 part of lutein, wherein the nucleotide and the lutein are optionally one or two of the nucleotide and the sum of the components does not exceed 100 parts. The invention also discloses a preparation method of the lactose-free infant formula food. The present invention aims to prepare a food product suitable for consumption by lactose intolerant infants.
Description
Technical Field
The invention relates to the technical field of infant food, in particular to lactose-free infant formula food and a preparation method thereof.
Background
At present, along with the improvement of the quality of life, people of different ages have corresponding meal-replacing foods, and then various good and bad foods exist, particularly baby foods, and considering that babies are in the stage of gradually perfecting various functions, the formula foods for the babies have corresponding standard requirements on edible foods, and in addition, the formula foods for the babies cannot feed breast milk or ordinary baby formula foods due to the influence of various diseases at present, and the formula foods for the babies become main food sources for the babies to live in early stage or for a long time.
Meanwhile, according to related reports, 76% -100% of Asian yellow race people are lacked in lactase, and 30% of China is lacked in lactase of children within 3 years old. Therefore, the infant formula needs to adopt lactose substitute, lactose intolerance is caused by the reduction of lactase activity due to congenital lactase deficiency or other pathological reasons, lactose cannot be digested and absorbed by small intestine and directly enters large intestine, and is fermented and hydrolyzed under the action of large intestine flora, so that clinical symptoms such as borborygmus, abdominal pain, rectal gas and diarrhea appear. The common infectious diarrhea of infants is also easy to cause secondary lactose intolerance, and the infants cannot eat the common milk powder, otherwise the diarrhea is delayed and not cured. In view of the above, there is a need to provide lactose-free infant formulas for use as a food supplement for lactose intolerant infants and young children.
Disclosure of Invention
The invention mainly aims to provide a lactose-free infant formula and a preparation method thereof, and aims to solve the technical problems that part of existing infant formula is lactose intolerant and common infant formula cannot be eaten.
In order to achieve the above object, the present invention provides a lactose-free infant formula comprising the following raw materials in parts by weight:
40-50 parts of vegetable fat powder;
25-40 parts of solid corn syrup and/or maltodextrin;
10-20 parts of lactose-free whole milk powder;
2-10 parts of separated whey protein powder rich in alpha-lactalbumin;
0.4-0.9 part of docosahexaenoic acid powder;
0.5-0.9 part of arachidonic acid powder;
2.0-3.0 parts of compound mineral;
0.3-0.7 part of compound vitamin;
0-0.05 part of nucleotide;
0-0.03 part of lutein;
wherein the nucleotide and lutein are optionally one or two of them, and the sum of each component is not more than 100 parts.
Optionally, the vegetable fat powder comprises the following raw materials in parts by weight:
40-50 parts of refined vegetable oil;
45-55 parts of glucose syrup;
4.0-5.0 parts of casein;
0.2-0.6 part of sodium dihydrogen phosphate;
0.2-0.6 part of potassium citrate;
0.45-0.65 part of sodium citrate;
1.5-2.3 parts of mono-diglycerol fatty acid ester;
0.05-0.13 part of citric acid fatty glyceride;
0.14 to 0.22 portion of potassium hydroxide, and the sum of all the components is not more than 100 portions.
Optionally, the refined vegetable oil comprises any one of corn oil, canola oil and coconut oil or a combination of at least two thereof.
Optionally, the fat content in the vegetable fat powder is 45% -55%, the linoleic acid content is 10% -15%, the alpha-linolenic acid content is 1.2% -2.1%, and the ratio of the linoleic acid to the alpha-linolenic acid is (5-15): 1.
optionally, the compound mineral comprises the following raw materials in parts by weight:
20-30 parts of tricalcium phosphate;
10-30 parts of monopotassium phosphate;
5.5-10 parts of calcium carbonate;
16-25 parts of potassium chloride;
8-22 parts of magnesium sulfate;
3-10 parts of sodium chloride;
0.16-0.4 part of copper sulfate;
0.5-1.3 parts of ferric pyrophosphate;
0.3-0.8 part of zinc sulfate;
0.4-1.6 parts of potassium iodide;
0.08-0.6 part of manganese sulfate;
0.08-0.3 part of sodium selenite;
15-25 parts of maltodextrin, and the sum of all the components is not more than 100 parts.
Optionally, the compound vitamin comprises the following raw materials in parts by weight:
5-10 parts of vitamin A acetate;
0.6-1.2 parts of cholecalciferol;
2-10 parts of dl-alpha-tocopheryl acetate;
0.12-0.6 part of plant menadione;
0.1-0.3 part of thiamine hydrochloride;
0.12-0.6 part of riboflavin;
0.04-0.18 part of pyridoxine hydrochloride;
15-30 parts of L-sodium ascorbate;
0.8-2.0 parts of D-calcium pantothenate;
0.2 to 1.0 portion of D-biotin;
0.12-0.5 part of folic acid;
0.4-1.6 parts of nicotinamide;
0.2-1.5 parts of cyanocobalamin;
30-50 parts of choline bitartrate;
2-12 parts of taurine;
3-10 parts of L-carnitine tartrate;
5-15 parts of maltodextrin, and the sum of the components is not more than 100 parts.
Optionally, the nucleotide comprises at least one of disodium 5' -cytidylate, disodium 5' -uridylate, adenosine 5' -monophosphate, disodium 5' -inosinate, and disodium 5' -guanylate.
Furthermore, to achieve the above object, the present invention also provides a method of preparing a lactose-free infant formula according to any of the above, comprising the steps of:
firstly, preparing vegetable fat powder:
dissolving glucose syrup and casein in water to obtain a mixed aqueous solution;
dissolving mono-diglycerol fatty acid ester and citric acid fatty glyceride in refined vegetable oil to obtain mixed oil solution;
mixing the mixed aqueous solution and the mixed oil solution, sequentially adding sodium dihydrogen phosphate, sodium citrate, potassium citrate and potassium hydroxide, uniformly mixing, and emulsifying to obtain an emulsion;
homogenizing, sterilizing and spray-drying the emulsion to obtain vegetable fat powder;
step two: preparing lactose-free whole milk powder;
standardizing fresh milk, pasteurizing and ultrafiltering sequentially to obtain filtrate;
adding lactase into the filtrate to obtain enzymatic hydrolysate;
carrying out enzyme deactivation, sterilization and spray drying on the enzymatic hydrolysate to obtain lactose-free whole milk powder;
step three: first-stage dry mixing treatment:
putting lactose-free whole milk powder, compound vitamins, compound mineral substances, lutein, nucleotide, docosahexaenoic acid powder and arachidonic acid powder in a predetermined proportion into a three-dimensional mixer, uniformly mixing to obtain a first material, and conveying the first material into a high-speed mixer through dense phase;
step four: secondary dry mixing treatment:
and putting the rest proportion of lactose-free whole milk powder, vegetable fat powder, solid corn syrup and/or maltodextrin and the separated lactalbumin powder rich in alpha-lactalbumin into a high-speed mixer to be uniformly mixed with the first material to obtain the lactose-free infant formula food.
Optionally, the isolated whey protein powder rich in alpha-lactalbumin is prepared by performing ultrafiltration, separation, spraying and drying on fresh milk, and the protein content is more than 85 wt%.
Optionally, the docosahexaenoic acid powder is extracted by fish oil or algae oil, and the arachidonic acid powder is extracted by Mortierella alpina.
The invention provides a lactose-free infant formula food, which takes lactoprotein as a protein source, hydrolyzes lactose of whole milk powder by an enzymolysis technology, adopts glucose, galactose, solid corn syrup and/or maltodextrin to replace the lactose, optimizes the combination of plant fat powder, solid corn syrup and/or maltodextrin, lactose-free whole milk powder, separated whey protein powder, docosahexaenoic acid (DHA), arachidonic acid (ARA), compound mineral substances, compound vitamins, nucleotides and lutein, has the sum of not more than 100 parts, and can meet the growth and development requirements of lactose-intolerant infants by energy and nutritional ingredients. In addition, the preparation method of the lactose-free infant formula food has reasonable process, easily controlled process parameters, stable quality of the produced product and high qualification rate.
Detailed Description
It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1
A lactose-free infant formula food is prepared from the following raw materials in parts by weight:
43 parts of vegetable fat powder, 33 parts of solid corn syrup, 14 parts of lactose-free whole milk powder, 6 parts of separated whey protein powder, 0.60 part of docosahexenoic acid powder (DHA), 0.7 part of arachidonic acid powder (ARA), 2.2 parts of compound mineral substances, 0.46 part of compound vitamins, 0.025 part of nucleotide and 0.015 part of lutein.
Wherein the vegetable fat powder is prepared from the following raw materials in parts by weight:
48 parts of refined vegetable oil, 45 parts of glucose syrup, 4.1 parts of casein, 0.35 part of sodium dihydrogen phosphate, 0.2 part of potassium citrate, 0.55 part of sodium citrate, 1.5 parts of mono-diglycerol fatty acid ester, 0.1 part of citric acid fatty glyceride and 0.2 part of potassium hydroxide.
The compound mineral is prepared from the following raw materials in parts by weight:
23 parts of tricalcium phosphate, 15 parts of monopotassium phosphate, 6.3 parts of calcium carbonate, 21 parts of potassium chloride, 10 parts of magnesium sulfate, 5 parts of sodium chloride, 0.28 part of copper sulfate, 1.0 part of ferric pyrophosphate, 0.5 part of zinc sulfate, 0.6 part of potassium iodide, 0.2 part of manganese sulfate, 0.12 part of sodium selenite and 17 parts of maltodextrin.
The compound vitamin is prepared from the following raw materials in parts by weight:
7.1 parts of vitamin A acetate, 0.9 part of cholecalciferol, 5 parts of dl-alpha-tocopherol acetate, 0.3 part of plant menadione, 0.15 part of thiamine hydrochloride, 0.25 part of riboflavin, 0.1 part of pyridoxine hydrochloride, 18 parts of L-sodium ascorbate, 1.2 parts of D-calcium pantothenate, 0.5 part of D-biotin, 0.2 part of folic acid, 0.8 part of nicotinamide, 0.5 part of cyanocobalamine, 40 parts of choline bitartrate, 7.0 parts of taurine, 6.0 parts of L-carnitine tartrate and 12 parts of maltodextrin.
The docosahexaenoic acid (DHA) powder is fish oil-derived DHA extract embedded powder.
The arachidonic acid powder (ARA) is an embedding powder of a mortierella alpina extract.
The refined vegetable oil used in the formula of this example is the primary source of fat in infant formula and is formulated primarily from vegetable oils, including one or a combination of corn oil, canola oil, and coconut oil. The oleic acid in the vegetable oil has a large proportion and can be used for making up the oleic acid in the infant formula nutritional food; and the linoleic acid in the corn oil and the rapeseed oil is very high, so that the linoleic acid can be used for making up the deficiency of the linoleic acid proportion in the infant nutritional formula food; preferably, rapeseed oil is used, which has a very high linoleic acid content and a much higher alpha-linolenic acid content than other vegetable oils. And controlling the fat content in the plant fat powder to be 45-55%, the linoleic acid content to be 10-15%, the alpha-linolenic acid content to be 1.2-2.1%, and the ratio of the linoleic acid to the alpha-linolenic acid to be (5-15): 1.
example 2
A lactose-free infant formula food is prepared from the following raw materials in parts by weight:
45 parts of vegetable fat powder, 31 parts of solid corn syrup, 14 parts of lactose-free whole milk powder, 6 parts of separated whey protein powder, 0.60 part of docosahexenoic acid powder (DHA), 0.825 part of arachidonic acid powder (ARA), 2.1 parts of compound mineral substances, 0.45 part of compound vitamins and 0.025 part of nucleotide.
The vegetable fat powder is prepared from the following raw materials in parts by weight:
46 parts of refined vegetable oil, 46 parts of glucose syrup, 5 parts of casein, 0.4 part of sodium dihydrogen phosphate, 0.2 part of potassium citrate, 0.6 part of sodium citrate, 1.5 parts of mono-diglycerol fatty acid ester, 0.1 part of citric acid fatty glyceride and 0.2 part of potassium hydroxide.
The refined vegetable oil comprises one or more of corn oil, rapeseed oil and coconut oil.
The compound mineral is prepared from the following raw materials in parts by weight:
22 parts of tricalcium phosphate, 15 parts of monopotassium phosphate, 7.0 parts of calcium carbonate, 21 parts of potassium chloride, 10.3 parts of magnesium sulfate, 5 parts of sodium chloride, 0.3 part of copper sulfate, 1.0 part of ferric pyrophosphate, 0.5 part of zinc sulfate, 0.6 part of potassium iodide, 0.2 part of manganese sulfate, 0.1 part of sodium selenite and 17 parts of maltodextrin.
The compound vitamin is prepared from the following raw materials in parts by weight:
7 parts of vitamin A acetate, 0.9 part of cholecalciferol, 5.5 parts of dl-alpha-tocopherol acetate, 0.4 part of plant menadione, 0.2 part of thiamine hydrochloride, 0.2 part of riboflavin, 0.1 part of pyridoxine hydrochloride, 20 parts of L-sodium ascorbate, 1.0 part of D-calcium pantothenate, 0.6 part of D-biotin, 0.25 part of folic acid, 1.0 part of nicotinamide, 0.55 part of cyanocobalamin, 38 parts of choline bitartrate, 7.3 parts of taurine, 5 parts of L-carnitine tartrate and 12 parts of maltodextrin.
The docosahexaenoic acid powder (DHA) is algae oil source DHA extract embedded powder.
The arachidonic acid powder (ARA) is an embedding powder of a mortierella alpina extract.
In the formula components of the embodiment, compared with the embodiment 1, the algae oil is used as a raw material for extracting docosahexenoic acid (DHA) powder, and the content of the component lutein is reduced, so that the formula food avoids contacting blue light as much as possible in the process of eating by infants, and the lutein has a strong antioxidant effect, can form an effective blue light filter in human retina, and reduces the oxidation damage caused by the blue light.
Example 3
A lactose-free infant formula food is prepared from the following raw materials in parts by weight:
46.5 parts of vegetable fat powder, 29 parts of maltodextrin, 14 parts of lactose-free whole milk powder, 6 parts of separated whey protein powder, 0.65 part of docosahexenoic acid powder (DHA), 0.8 part of arachidonic acid powder (ARA), 2.5 parts of compound mineral substances, 0.5 part of compound vitamins, 0.03 part of nucleotide and 0.02 part of lutein.
The vegetable fat powder is prepared from the following raw materials in parts by weight:
47 parts of refined vegetable oil, 45 parts of glucose syrup, 4.5 parts of casein, 0.4 part of sodium dihydrogen phosphate, 0.25 part of potassium citrate, 0.55 part of sodium citrate, 2.0 parts of mono-diglycerol fatty acid ester, 0.1 part of citric acid fatty glyceride and 0.2 part of potassium hydroxide.
The refined vegetable oil comprises one or more of corn oil, rapeseed oil and coconut oil.
The compound mineral is prepared from the following raw materials in parts by weight:
25 parts of tricalcium phosphate, 15 parts of monopotassium phosphate, 7.0 parts of calcium carbonate, 20 parts of potassium chloride, 10 parts of magnesium sulfate, 4.4 parts of sodium chloride, 0.25 part of copper sulfate, 1.0 part of ferric pyrophosphate, 0.45 part of zinc sulfate, 0.6 part of potassium iodide, 0.2 part of manganese sulfate, 0.1 part of sodium selenite and 16 parts of maltodextrin.
The compound vitamin is prepared from the following raw materials in parts by weight:
7.0 parts of vitamin A acetate, 0.9 part of cholecalciferol, 5.5 parts of dl-alpha-tocopherol acetate, 0.4 part of plant menadione, 0.2 part of thiamine hydrochloride, 0.2 part of riboflavin, 0.1 part of pyridoxine hydrochloride, 20 parts of L-sodium ascorbate, 1.0 part of D-calcium pantothenate, 0.6 part of D-biotin, 0.25 part of folic acid, 1.0 part of nicotinamide, 0.55 part of cyanocobalamin, 38.0 parts of choline bitartrate, 7.3 parts of taurine, 5.0 parts of L-carnitine tartrate and 12.0 parts of maltodextrin.
The docosahexaenoic acid (DHA) powder is fish oil-derived DHA extract embedded powder.
The arachidonic acid powder (ARA) is an embedding powder of a mortierella alpina extract.
Compared with the formula of example 1, the formula of this example has increased the content of vegetable fat powder, so that the fat content of the obtained formula food is slightly higher than that of the formula food in example 1, and maltodextrin is used to replace lactose, thereby preparing the lactose-free formula food.
Example 4
A lactose-free infant formula food is prepared from the following raw materials in parts by weight:
45 parts of vegetable fat powder, 32 parts of maltodextrin, 14 parts of lactose-free whole milk powder, 6.0 parts of separated whey protein powder, 0.68 part of docosahexenoic acid powder (DHA), 0.8 part of arachidonic acid powder (ARA), 2.9 parts of compound mineral substances, 0.6 part of compound vitamins and 0.02 part of lutein.
The vegetable fat powder is prepared from the following raw materials in parts by weight:
47 parts of refined vegetable oil, 45 parts of glucose syrup, 4.5 parts of casein, 0.4 part of sodium dihydrogen phosphate, 0.25 part of potassium citrate, 0.55 part of sodium citrate, 2.0 parts of mono-diglycerol fatty acid ester, 0.1 part of citric acid fatty glyceride and 0.2 part of potassium hydroxide.
The refined vegetable oil comprises one or more of corn oil, rapeseed oil and coconut oil.
The compound mineral is prepared from the following raw materials in parts by weight:
25 parts of tricalcium phosphate, 15 parts of monopotassium phosphate, 7.0 parts of calcium carbonate, 20 parts of potassium chloride, 10 parts of magnesium sulfate, 4.4 parts of sodium chloride, 0.25 part of copper sulfate, 1.0 part of ferric pyrophosphate, 0.45 part of zinc sulfate, 0.6 part of potassium iodide, 0.2 part of manganese sulfate, 0.1 part of sodium selenite and 16 parts of maltodextrin.
The compound vitamin is prepared from the following raw materials in parts by weight:
7.0 parts of vitamin A acetate, 0.75 part of cholecalciferol, 5.5 parts of dl-alpha-tocopherol acetate, 0.4 part of plant menadione, 0.2 part of thiamine hydrochloride, 0.2 part of riboflavin, 0.1 part of pyridoxine hydrochloride, 21 parts of sodium L-ascorbate, 1.0 part of D-calcium pantothenate, 0.5 part of D-biotin, 0.24 part of folic acid, 1.0 part of nicotinamide, 0.71 part of cyanocobalamin, 37.0 parts of choline bitartrate, 7.0 parts of taurine, 5.4 parts of L-carnitine tartrate and 12.0 parts of maltodextrin.
The docosahexaenoic acid (DHA) powder can be fish oil source DHA extract embedded powder or algae oil source DHA extract embedded powder.
The arachidonic acid powder (ARA) is an embedding powder of a mortierella alpina extract.
Although the formula components of the present example have reduced content of nucleotides compared to example 3, exogenous nucleotides have the functions of promoting growth and development and enhancing immunity, the formula food without nucleotides can be eaten by infants when they eat human milk at the same time, because human milk contains a large amount of nucleotides.
Meanwhile, a certain amount of unsaturated fatty acid arachidonic acid powder (ARA) and docosahexaenoic acid powder (DHA) are added in the above embodiments, because ARA and DHA are important fatty acids indispensable to brain and nerve cell activities, studies show that ARA and DHA have positive effects on brain development and retina of newborn infants. And the raw milk is adopted to prepare the lactalbumin rich in alpha-lactalbumin, because the lactalbumin rich in alpha-lactalbumin not only contains rich tryptophan, but also has higher relative concentration of other essential amino acids. Alpha-lactalbumin contains tryptophan which plays an important role in growth, development and metabolism of human body, is called second essential amino acid and is the precursor of neurotransmitter 5-hydroxytryptamine and melatonin, and the two neurotransmitters are secreted by pineal cells in human body. 5-hydroxytryptamine is mainly secreted in the daytime and is a neurotransmitter that regulates mood, appetite, and behavior; while melatonin is secreted at night and is an endogenous sleep inducer. These two neurotransmitters are important regulators of the body's biological clock, help infants sleep, promote infant brain development, and enable children to have good emotional control from a young age. In addition, alpha-lactalbumin also contains cystine/cysteine, which is a constituent of glutathione and can prevent the oxidative damage of peroxides. Cystine/cysteine can be used as the precursor of taurine, and is beneficial to the synthesis of bile acid, the absorption of fatty acid and the development of nervous system. And the protein content in the separated whey protein powder containing alpha-lactalbumin needs to be controlled to be more than 85wt percent.
Further, the raw materials with different mass components in the above examples 1 to 4 are respectively prepared by a dry-wet composite process, specifically, the method comprises the following steps:
firstly, preparing vegetable fat powder:
dissolving glucose syrup and casein in water to obtain mixed water solution, wherein the water solution is continuously heated to room temperature until the glucose syrup and the casein are dissolved in the water under stirring, the maximum temperature is controlled to be lower than 60 ℃, and the mass of the water is 2.5-4 times of the mass sum of the glucose syrup and the casein.
Dissolving mono-diglycerol fatty acid ester and citric acid fatty glyceride in refined vegetable oil at room temperature to obtain mixed oil solution;
mixing the mixed aqueous solution and the mixed oil solution, adding a solution obtained by uniformly mixing sodium dihydrogen phosphate, sodium citrate, potassium citrate and potassium hydroxide, and emulsifying for 20-30 minutes to obtain an emulsion;
homogenizing, sterilizing and spray-drying the emulsion to obtain vegetable fat powder;
step two: preparing lactose-free whole milk powder;
performing pasteurization and ultrafiltration treatment on raw and fresh milk in sequence to obtain filtrate;
adding lactase into the filtrate to obtain enzymatic hydrolysate;
carrying out enzyme deactivation, sterilization and spray drying on the enzymatic hydrolysate to obtain lactose-free whole milk powder;
step three: first-stage dry mixing treatment:
putting lactose-free whole milk powder, compound vitamins, compound mineral substances, lutein, nucleotide, docosahexaenoic acid powder and arachidonic acid powder in a predetermined proportion into a three-dimensional mixer, uniformly mixing to obtain a first material, and hermetically conveying the first material into a high-speed mixer;
step four: secondary dry mixing treatment:
and (3) putting the lactose-free whole milk powder, the vegetable fat powder, the solid corn syrup and/or the maltodextrin and the separated whey protein powder rich in the alpha-lactalbumin into a high-speed mixer according to the rest proportion, and uniformly mixing the materials with the first material to obtain the lactose-free infant formula food.
And performing modified atmosphere packaging on the obtained lactose-free formula food by filling nitrogen or carbon dioxide in vacuum to obtain a final packaged product.
Wherein, the preparation sequence of the first step and the second step is not limited, and the proportion of the lactose-free whole milk powder subjected to dry mixing treatment in the third step and the fourth step is 3:7-7: 3.
Further, the lactose-free infant formulas prepared according to the different quality ingredient materials of examples 1 to 4 above were subjected to various index tests, and the results are shown in table 1.
TABLE 1 nutrient assay
From the test results, the indexes of the lactose-free formula food meet the requirements of national standard GB25596-2010 food safety standard infant formula food general rule for special medical use, and further the lactose-intolerant infant formula food meets the nutritional requirements of infants with lactose intolerance.
Claims (10)
1. A lactose-free infant formula is characterized by comprising the following raw materials in parts by weight:
40-50 parts of vegetable fat powder;
25-40 parts of solid corn syrup and/or maltodextrin;
10-20 parts of lactose-free whole milk powder;
2-10 parts of separated whey protein powder rich in alpha-lactalbumin;
0.4-0.9 part of docosahexaenoic acid powder;
0.5-0.9 part of arachidonic acid powder;
2.0-3.0 parts of compound mineral;
0.3-0.7 part of compound vitamin;
0-0.05 part of nucleotide;
0-0.03 part of lutein;
wherein the nucleotide and lutein are optionally one or two of them, and the sum of each component is not more than 100 parts.
2. The lactose-free infant formula of claim 1 wherein the vegetable fat powder comprises the following raw materials in parts by weight:
40-50 parts of refined vegetable oil;
45-55 parts of glucose syrup;
4.0-5.0 parts of casein;
0.2-0.6 part of sodium dihydrogen phosphate;
0.2-0.6 part of potassium citrate;
0.45-0.65 part of sodium citrate;
1.5-2.3 parts of mono-diglycerol fatty acid ester;
0.05-0.13 part of citric acid fatty glyceride;
0.14 to 0.22 portion of potassium hydroxide, and the sum of all the components is not more than 100 portions.
3. The lactose-free infant formula of claim 2 wherein the refined vegetable oil comprises any one or a combination of at least two of corn oil, canola oil and coconut oil.
4. The lactose-free infant formula according to claim 2, wherein the fat content in the vegetable fat powder is 45-55%, the linoleic acid content is 10-15%, the alpha-linolenic acid content is 1.2-2.1%, and the ratio of linoleic acid to alpha-linolenic acid is (5-15): 1.
5. the lactose-free infant formula of claim 1 wherein the formulated minerals comprise the following raw materials in parts by weight:
20-30 parts of tricalcium phosphate;
10-30 parts of monopotassium phosphate;
5.5-10 parts of calcium carbonate;
16-25 parts of potassium chloride;
8-22 parts of magnesium sulfate;
3-10 parts of sodium chloride;
0.16-0.4 part of copper sulfate;
0.5-1.3 parts of ferric pyrophosphate;
0.3-0.8 part of zinc sulfate;
0.4-1.6 parts of potassium iodide;
0.08-0.6 part of manganese sulfate;
0.08-0.3 part of sodium selenite;
15-25 parts of maltodextrin, and the sum of all the components is not more than 100 parts.
6. The lactose-free infant formula of claim 1 wherein the vitamin blend comprises the following raw materials in parts by weight:
5-10 parts of vitamin A acetate;
0.6-1.2 parts of cholecalciferol;
2-10 parts of dl-alpha-tocopheryl acetate;
0.12-0.6 part of plant menadione;
0.1-0.3 part of thiamine hydrochloride;
0.12-0.6 part of riboflavin;
0.04-0.18 part of pyridoxine hydrochloride;
15-30 parts of sodium L-ascorbate;
0.8-2.0 parts of D-calcium pantothenate;
0.2 to 1.0 portion of D-biotin;
0.12-0.5 part of folic acid;
0.4-1.6 parts of nicotinamide;
0.2-1.5 parts of cyanocobalamin;
30-50 parts of choline bitartrate;
2-12 parts of taurine;
3-10 parts of L-carnitine tartrate;
5-15 parts of maltodextrin, and the sum of the components is not more than 100 parts.
7. The lactose-free infant formula of claim 1 wherein the nucleotides include at least one of disodium 5' -cytidylate, disodium 5' -uridylate, adenosine 5' monophosphate, disodium 5' -inosinate, and disodium 5' -guanylate.
8. A process for the preparation of a lactose-free infant formula according to any of claims 1 to 7, comprising the steps of:
firstly, preparing vegetable fat powder:
dissolving glucose syrup and casein in water to obtain a mixed aqueous solution;
dissolving mono-diglycerol fatty acid ester and citric acid fatty glyceride in refined vegetable oil to obtain mixed oil solution;
mixing the mixed aqueous solution and the mixed oil solution, adding a solution obtained by uniformly mixing sodium dihydrogen phosphate, sodium citrate, potassium citrate and potassium hydroxide into the mixed aqueous solution, and emulsifying to obtain an emulsion;
homogenizing, sterilizing and spray-drying the emulsion to obtain vegetable fat powder;
step two: preparing lactose-free whole milk powder;
performing pasteurization and ultrafiltration treatment on raw and fresh milk in sequence to obtain filtrate;
adding lactase into the filtrate to obtain enzymatic hydrolysate;
carrying out enzyme deactivation, sterilization and spray drying on the enzymatic hydrolysate to obtain lactose-free whole milk powder;
step three: first-stage dry mixing treatment:
the lactose-free full cream milk powder, compound vitamins, compound mineral substances, lutein, nucleotide, docosahexaenoic acid powder and arachidonic acid powder in a predetermined proportion are put into a three-dimensional mixer to be uniformly mixed to obtain a first material, and the first material is hermetically conveyed into a high-speed mixer;
step four: secondary dry mixing treatment:
and putting the rest proportion of lactose-free whole milk powder, vegetable fat powder, solid corn syrup and/or maltodextrin and the separated lactalbumin powder rich in alpha-lactalbumin into a high-speed mixer to be uniformly mixed with the first material to obtain the lactose-free infant formula food.
9. The lactose-free infant formula of claim 8 wherein the isolated whey protein powder enriched in alpha-lactalbumin is obtained from fresh cow's milk by ultrafiltration, separation, spray drying and wherein the protein content is above 85 wt%.
10. The lactose-free infant formula of claim 8 wherein the docosahexaenoic acid powder is extracted by fish oil or algae oil and the arachidonic acid powder is extracted by mortierella alpina.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111231618.5A CN113907340A (en) | 2021-10-22 | 2021-10-22 | Lactose-free infant formula and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111231618.5A CN113907340A (en) | 2021-10-22 | 2021-10-22 | Lactose-free infant formula and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113907340A true CN113907340A (en) | 2022-01-11 |
Family
ID=79242446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111231618.5A Withdrawn CN113907340A (en) | 2021-10-22 | 2021-10-22 | Lactose-free infant formula and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113907340A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060286252A1 (en) * | 2005-06-01 | 2006-12-21 | Nagendra Rangavajla | Low-lactose partially hydrolyzed infant formula |
| CN105638908A (en) * | 2016-03-31 | 2016-06-08 | 东北农业大学 | Formula milk powder for infants of 0-6 months and capable of preventing lactose intolerance and protein allergy |
| CN105831253A (en) * | 2016-03-23 | 2016-08-10 | 无锡超科食品科技有限公司 | Lactose-free infant formula milk powder and preparation method thereof |
| CN108967557A (en) * | 2018-09-29 | 2018-12-11 | 贝因美（杭州）食品研究院有限公司 | A kind of infant formula and preparation method thereof |
| CN109156817A (en) * | 2018-08-01 | 2019-01-08 | 贝因美（杭州）食品研究院有限公司 | A kind of lactose free infant formula food and preparation method thereof |
-
2021
- 2021-10-22 CN CN202111231618.5A patent/CN113907340A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060286252A1 (en) * | 2005-06-01 | 2006-12-21 | Nagendra Rangavajla | Low-lactose partially hydrolyzed infant formula |
| CN105831253A (en) * | 2016-03-23 | 2016-08-10 | 无锡超科食品科技有限公司 | Lactose-free infant formula milk powder and preparation method thereof |
| CN105638908A (en) * | 2016-03-31 | 2016-06-08 | 东北农业大学 | Formula milk powder for infants of 0-6 months and capable of preventing lactose intolerance and protein allergy |
| CN109156817A (en) * | 2018-08-01 | 2019-01-08 | 贝因美（杭州）食品研究院有限公司 | A kind of lactose free infant formula food and preparation method thereof |
| CN108967557A (en) * | 2018-09-29 | 2018-12-11 | 贝因美（杭州）食品研究院有限公司 | A kind of infant formula and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 孙俊;杨娜;吴芝岳;宋丽丽;: "无乳糖配方粉的研究进展及应用", 食品安全导刊 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100391353C (en) | Formula milk powder for babies | |
| US4303692A (en) | Infant milk formula | |
| AU2010203123B2 (en) | Infant formula containing nucleotides | |
| CN102422900A (en) | Formula milk powder for promoting absorption of fatty acid and calcium and preparation method thereof | |
| ZA200600601B (en) | Infant or follow-on formula | |
| CN113397164A (en) | Special medical full-nutrition formula food for improving immunity and preparation method thereof | |
| CN108741048A (en) | A kind of infant nutrient packet and preparation method thereof | |
| CN116686977B (en) | Dietary supplement with dual nutrition supplementation for pregnant women and fetuses and preparation method thereof | |
| CN110604180A (en) | Formula and preparation process of novel infant milk powder | |
| CN113907340A (en) | Lactose-free infant formula and preparation method thereof | |
| Mary Sue Brady MS et al. | Specialized formulas and feedings for infants with malabsorption or formula intolerance | |
| CN115500394A (en) | Fatty acid ester composition containing LPLa triglyceride | |
| MXPA04007540A (en) | Human milk supplement. | |
| RU2703172C2 (en) | Feeding for infants with hydrolysed protein and palmitic acid | |
| US20210037854A1 (en) | Eggs rich in nutrients of alpha-linolenic acid and dha, breeding method of laying hens, and feed additive | |
| CN115191604B (en) | Nutritional composition, food containing nutritional composition and application | |
| EP3897213B1 (en) | Protein compositions with high isoelectric proteins | |
| CN111700117A (en) | Organic infant formula milk powder | |
| RU2417613C1 (en) | Pasteurised dairy product based on goat milk for pregnant and nursing women alimentation | |
| JP3247786B2 (en) | Foods Highly Containing β-Casein | |
| JP4694053B2 (en) | Infant nutrition composition | |
| CN117223848A (en) | Powdered nutritional composition suitable for premature infants and preparation method thereof | |
| CN112352948A (en) | Casein balanced type total nutrient powder prepared by wet process and preparation method | |
| CN115053928A (en) | Milk powder replacing milk for newborn and preparation method thereof | |
| RU2440767C1 (en) | Sterilised dairy product based on goat milk for pregnant and nursing women alimentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220111 |
|
| WW01 | Invention patent application withdrawn after publication |